Most generalized MG patients have ocular symptoms at presentation, which progress and cause generalized MG involving the ...
Dr. Stuart Himmelstein, DC, a Philadelphia-based chiropractor, examines how peripheral neuropathy is evaluated in ...
Everyday Health on MSN
Exploring second-line therapies for CIDP
If your chronic inflammatory demyelinating polyneuropathy (CIDP) treatment has hit a plateau, new options like FcRn ...
If you or a loved one are living with hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM), you are likely well-acquainted with the challenges of heart health. You know the fatigue, the ...
Olympian Michael Klim forged his reputation on strength and athleticism. But after being blindsided by an incurable ...
Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron® treatment to be well ...
The company said Tuesday that the FDA lifted the hold on an Investigational New Drug Application for a phase 3 clinical trial of nexiguran ziclumeran, or nex-z, for patients with a genetic disease ...
In a new study, researchers found that among patients with diabetic peripheral neuropathy (DPN) and low serum vitamin B12 ...
Orphan Drug Designation applies to approximately 50,000 Patients who predominantly suffer from severe chronic pain due ...
Plan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 ...
Intellia Therapeutics said on Tuesday that the U.S. drug regulator has lifted a clinical hold on one of its late-stage gene ...
Gene editing company Intellia Therapeutics has announced that the US Food and Drug Administration (FDA) has removed the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results